Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, adding:
”Choosing the right anticoagulant for acute venous thromboembolism (VTE) often comes down to balancing efficacy with bleeding risk.
A recent international randomized trial compared apixaban and rivaroxaban, two of the most commonly used direct oral anticoagulants for treating acute pulmonary embolism and proximal deep-vein thrombosis.
Study design
- 2,760 patients with acute symptomatic VTE
- Randomized 1:1 to apixaban or rivaroxaban
- 3-month treatment period
- Primary endpoint: clinically relevant bleeding (major plus clinically relevant non-major bleeding)
Dosing
- Apixaban: 10 mg BID for 7 days – 5 mg BID
- Rivaroxaban: 15 mg BID for 21 days – 20 mg daily
Key results
Clinically relevant bleeding:
- Apixaban: 3.3%
- Rivaroxaban: 7.1%
- Relative risk: 0.46 (95% CI 0.33–0.65, P < 0.001)
This represents ~54% lower risk of clinically relevant bleeding with apixaban over the 3-month treatment period.
Mortality remained very low in both groups
- Apixaban: 0.1%
- Rivaroxaban: 0.3%
Takeaway
Among patients with acute VTE, apixaban demonstrated a significantly lower bleeding risk compared with rivaroxaban, while maintaining similar overall safety outcomes.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger, for the COBRRA Trial Investigators
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List
-
Oct 30, 2026, 15:53Ilenia Calcaterra: Patient Blood Management Across Complex Hematological Conditions
-
Oct 30, 2026, 15:40Isabella Presch: The Practicalities of Gene Therapy Adoption in Hemophilia
-
Oct 30, 2026, 15:12Edward C.C. Wong: Navigating the Implications of the 2026 ASH Guidelines for Blood Donation
-
Oct 30, 2026, 14:53Pall T. Onundarson: Anticoagulation Guidelines Under the Influence of Pharmaceuticalisation
-
Oct 30, 2026, 14:27Isabella Presch: From Innovation to Accessibility in Cell and Gene Therapy
-
Oct 30, 2026, 14:00Abdul Mannan: A Negative PCR Does Not Exclude β-Thalassaemia
-
Oct 30, 2026, 13:53Matteo Foschi: Can Thrombolysis Safely Treat Stroke After Cardiac Procedures?